Cantor Fitzgerald Lowers Lucid Diagnostics (NASDAQ:LUCD) Price Target to $2.00

Lucid Diagnostics (NASDAQ:LUCD) had its target price lowered by Cantor Fitzgerald from $3.00 to $2.00 in a research report report published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other analysts also recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $2.50 target price on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research note on Thursday, November 14th. Canaccord Genuity Group raised Lucid Diagnostics to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, Ascendiant Capital Markets reduced their price objective on Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating for the company in a research report on Tuesday, September 10th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Lucid Diagnostics has an average rating of “Buy” and a consensus price target of $3.69.

Lucid Diagnostics Stock Down 3.7 %

NASDAQ LUCD opened at $0.95 on Friday. The firm has a market capitalization of $56.37 million, a PE ratio of -0.83 and a beta of 1.41. The stock’s 50 day moving average is $0.87 and its 200 day moving average is $0.85. Lucid Diagnostics has a twelve month low of $0.63 and a twelve month high of $1.58.

Hedge Funds Weigh In On Lucid Diagnostics

A hedge fund recently raised its stake in Lucid Diagnostics stock. Virtu Financial LLC boosted its holdings in Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 34,671 shares of the company’s stock after buying an additional 13,835 shares during the period. Virtu Financial LLC owned 0.07% of Lucid Diagnostics worth $28,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.